our our continue for thank afternoon, Good help proud I'm and patients novel cancer and as to we technologies. Thank with Personalis very at you, you joining team us. fight Caroline. everyone, of
disease minimal For and treatment. market. commonly to liquid cancer billion Personalis of blood, which the biopsies its stands MRD into for in a and one is has the market you instead welcome. testing fast-growing joining invasive our our called MRD after a detect leaders is of time, test, of to the involves one residual is using monitor for first calls this of recurrence a in with MRD those space. or as ultrasensitive And Personalis MRD of imaging first market. therapy leader emerged kind expected to $XX mature
The biopsy
fragments to spot about able are one circulating when DNA blood. technologies only tumor Our DNA fragment there's in cancer in X of the million
used the by of laid companies this top and by platforms trial power treatment Our drive Personalis revenue in of results a personalize in new XXXX. ways world's million new to to to our many strategy year, biopharma are improve generation out $XXX we clinical to
Earlier therapies.
has shift a for milestone used effect vaccines biopharma driven for growth second XX% our million, XXX% cancer as by MRD engines demand In into year-over-year. up This at as well the tumor demand we quarter, core which and mode. our its been us business, operational create profiling was this its year-over-year, NeXT X Now strong personalized to revenue has patients led is growth product that for achieved by increasing product higher $XX.X growth Personal. grew to our of
$XX the $X helped year revenue we for range full to us in pleased review also We're year top increase quarter million, shortly. our our progress cost full the to revenue $XX million. to
I'll while able been our now growth on also Aaron as deliver expect of QX strong to guidance growth making line will have growth this by both now -- margins X to engines. this particularly Our and cover improvements and million
is as into a personals clinical diagnostic focus Win-in-MRD engine most we growth powerhouse. turning important first The the on
recurrence payers significant cancer find drive trials, unlock three, value evidence our patients, developing its X MRD to evidence partner-centric a out and on and reimbursement by disease noted, and biopharma to model. top global partners executing adoption with We deep our been commercialize on with an NeXT uses Win-in-MRD partnering pillars. effectiveness. the I our to focus approach ago, clinical X biopsy X NeXT robust Personal of liquid leverage partners. strategy we've minimal therapy quarters can testing monitor the a by for by One, accelerate As and or Two, cancer collaborators; growth revenue of ultrasensitive Personal laid relationships empower and clinical where use residual types and
earlier, more patients who and we're ahead patients NeXT promise studies cancer recurrence a reimbursement avoiding how the that classified have MRD support of DNA potentially clinical data sooner meaning The circulating IO toxicities Now to data procedures result we're lung delve patients months unnecessary tumor the test many monitor. doctor detect indicate cancer may Personal's and ultimately from and Having into therapy do also with holds breast the we negative better that care detect evidence usage largely cancer, that can The a negative, and experience explained and money. we imaging. across indicate developing outcomes. to in can been previously are to clinical doesn't able multiple pillar, our to from the first seek therapies not confidence recurrence. The as out see date potentially system this done studies treatment those now cancer saving suggests allow than to health de-escalate
breast on data be ultrasensitive cancer focus is win intentional, cancer approach, demonstrated elaborate they and an recur, in detection the and is bit To breast can without can our DNA is these aggressive early difficult shed markets. so critical. NeXT is very cancers Lung that cancer our when in approach. these Personal on a indications Our to detect lung so and blood, little
on decision provided ideal make us. the IO indications from insights are test. our cancer switch on the that first
In clinic. alongside our we've the is lung been we NeXT into being is test, marketed just We and started October test XX therapy patients the put we to appropriate which commercial therapy. monitoring patients For XXXX, an MRD Medicare breast adding ultrasensitive requires to incrementally. These Personal for launched treatment access therapy, and NeXT potential monitoring believe journey in by early the factors program, tumor cancer, our help reimbursed profiling of doctors ultrasensitive with used commercial Dx,
intention we more stated, to doctors As gradually receive the we previously until add our is reimbursement. program into
tests XXX increase the Our this we be the first XX% quarter-over-quarter clinical as a in growth of continues quarter, the second healthy results to from delivered XXX quarter delivered year. in
Early that a clinicians fuel in NeXT In actionability leap addition, from commercial are has late Personal the our expect additional and quarter, feedback in Tempus been seeing growth. commenced of we launch second this their approach. to
MRD report million, clinical remember, our which the unmask blood, that in tumor region this expect We one earlier, and forward and region report a we see to actionability Personal of are, have that XX% is cancer and in cancer-free. testing testing previously a and that you also negative samples have with cancer if is part need, many sooner leap in therapy in of physicians ctDNA quantify X deescalating them ultrasensitive for ultrasensitive DNA is results a we and see hard from therapy the DNA have intervene test determines If fragment monitoring to with it. sensitivity been recurrence to them in early fragment has is the on are get tumor consider range. been they About to confidence field. to in ctDNA. range that means ctDNA down our just million call positive our anecdotes had we've to analytic MRD circulating That when it allowing with jump the consistently. extra the NeXT discrimination related This more range. the ultrasensitive can we in The blood test see access patients patients means and circulating see that of our DNA the fact, in X more the the patient doctors there negative management about
Indeed, per
a the female receiving Personal example, Northeast breast test. positive tested with from our therapy patient NeXT for For cancer
over cancer the became low Our range trended ultrasensitive several patient, the levels for months. finally detected physicians And of and the downwards until for luckily patient's saw traces this undetectable. cancer
in like provide the patient. to therapy inform reassurance both patients can future potentially the off monitoring help and Continued taking and doctor this the
institutions the during and that then a of that sets the our a or leading NeXT which in the breast worth the VHIO.
The global were we of and imaging the Medicare medium are NeXT Marsden of potentially of Personal dossiers highlighted results many to are cancer manuscripts each used The studies second Moving focused leading individual evidence the included ASCO results XX early-stage our collaborators of join detecting these across showed clinical Vall of world. work published, our highlighted NeXT noting. provided study we're with X show and These in subtypes.
There scans. than to traces ultimately the other what Personal submit around patients cancer Tracer were Medicare. and top are cancer X also X Farber breast Royal cancer months scans Royal were to Cancer be major compelling. continue our a study for data for and triple-negative well medium patients working across with Dana One with X ASCO and ahead in journals, at the access our VHIO studies was for followed that Institute cancer the Neoadjuvant greater submit are immunotherapy to the for U.K., outcomes for d'Hebron, Personal including about those data used of indications the with indicating response presentation The studies, submit and and ASCO to X are one building pan XX monitoring. detected the breast therapy. of to deepen reimbursement. us HERX-positive and for for can HERX was neoadjuvant breast is work work during immunotherapy is HER-positive, centers In cancer comprehensive. NeXT d'Hebron Investigators these Royal on predict the cancer one of positive subtypes peer-reviewed XXX publishing this to thought the to reimbursement. of Vall tumor years. cancer the in in we try study we in Marsden were the patients Similar calls Duke, backbone gain to pillar, the at talked study study, a studies NeXT with removed. the patients of before results before Research gain breast importance work patients Tracer leaders in all included form immunotherapy cancer reimbursement patients Personal patients second be In for and the given for correlated VHIO to response. Medicare cancer of monitoring to cancer and and breast is key immunotherapy Europe, to different seeing the our predict podium manuscripts in imaging study is Both Marsden, of patients. in test previous have case Marsden X broad cancer with could lung to a is the to Once are In Royal to could to the these receiving which in therapy surgery personal efforts shrink before step of webinar,
the clinical pillar most trials. strategy have ultrasensitive of and and an world's relationship biopharma need most to around NeXT our to -- is top enter recently We're Personal the approach use of ASCO. of with to discussions patients our with NeXT drive third NeXT our into generate the to Personal excuse clinical want me, engaged appropriate Customers test most the ensure Personal excitement companies leverage most trials. at continued that and biopharma from The
likely negative most believe For assay testing example, recurrence. that our that we to have patients means a ultrasensitive are much
can from biopharma an biopharma optimize customers are trials. patients then to out intervention, promise be to that holding excellent Our a NeXT less Personal approach the will benefit therapeutic expect these likely that
accelerate. and revenue expect from millions booked date growth have projects to customers of dollars the biopharma MRD of We from to
NeXT Now the then services products and review, Personal we Personalis reimbursement us. channel deal and we commercialize Personalis Commercializing clinical recently, the growth. launch in fair of to is in market processing while they the leverage NeXT accelerate the their their with on XXX-plus watch. to a Personal salespeople and obtaining commercial triggered, samples Personal Tempus NeXT co-commercialize million patients pillar. and fully to move Overall, provide under model. In our to using clinics quickly customers. responsible exercises payments value be all health our the in expect $XX partnership for announced will lab, key to announced invoicing to payers To insurance Tempus Tempus' market the partner-centric with final for the be oncologists and milestone December, fourth worth paying our for should arrangement, Tempus approximately Tempus
expect us to work efforts balance
We're grow together, learning relationship is the our refining investments. together up well we're business requisition, working cash growth and on We additional seamlessly is to how year our efforts partners, the to samples The the The accelerated backside this of allow ramp message Tempus' minimal set purposely and extremely approval. reimbursement to as of oncologists. to This Tempus lab. we're with systems to integrating to drive to the processing date. our for now commercial quickly sent goal on our way,
doctors, we're together, and we're creating for confident and great our that and payers. cultures well something teams patients Our work
our to We've biopharma our therapies. establish Win-in-MRD Personal a tension, While our test. made also with leveraging to deepen strides we the use as pioneer strategy tension, new average with to who MRD made ImmunoID second our progress growth first offering relationships customers with NeXT NeXT platform leading growth
XXX% grew year-over-year, use primarily solid ways. Customers had our performance across business biopharma platform in ImmunoID our we portfolio. product NeXT Our and X
power to find platform our enable efforts. can their new discovery leverage and they that biomarkers research First, translational drug and insights
you an mRNA personalized molecular and partner, Moderna vaccine therapy. the fingerprint previously partnership its create use to personalized Second, cancer cancer is us our Moderna for is driver collaboration and tumor develop patients, in XXXX. our our a a program. with their utilizing our Merck patient's Moderna enrolling platform companies platform We of in the and important PCV which of Moderna, in market XXXX or to revenue with about in told
We space in work have several as other well. partners this that
partners inside our customers. of approach and enterprise third platforms And growth adopt to solutions. we service our our relationships, power growing their Personalis technologies The engine is as these
platform product For example, scale build part a while Natera has MRD as of their to they them Exxon help work leveraged capabilities. our in-house to
reached VA to product XXXX. purchase With the to we this other the program note, scaling quarter new to power we're plan the contract over a of years. the diagnostic VA arrangement. parts planned, As in order capabilities in our XXXX, discussions with have The enterprise extend lab, will run by down VA the our important XX should second Program, MRD and sequencing looking they in support this now where September. renew that up year, The our those enterprise point to Natera informed genes with work the us and no
A the work clinical helped quickly, relationship of program can and commercial is affect national expect critical veterans. the parts how the the by we research end intention power another at we their genome they've wind VA. of they Veteran and lifestyle current strategic accelerating projects, health exploring of business. PCV, capacity and a to our biopharma other shift to for business, end I receive whole also business utilizes Million our additional We've having expect
I Aaron, I a it of turn updates. Before to couple important over have corporate
the testing making partner approaches completed operate and cancer cancer for to ultrasensitive tumor-informed to the for field broadens benefits sees approaches or to tumor-informed an solidify each MRD. scale to approach monitoring value detection cross-license more and tumor-informed Myriad MRD First, The Myriad freedom and and genome to covering patients. help ultrasensitive cancer standard pioneering market access and are each enabling MRD minimal foundational key testing of approaches detect we Both Genetics states the companies an deep recurrent therapy entered the refined company's each we agreement of MRD partner have MRD benefits care. Personalis alternative recently agreement residual in and approaches. is power to in developed and to to disease, early with test, of states patients in
running and it. cost putting Myriad confidence our our with turn outcome I'll that One, review license Personalis. financial to on its Foresight, we of settled were With now royalties create us focus our us. in agreement cross-license results. the for MRD litigation over ability This that, our granting litigation Aaron the that, to We business years from should secondly, resulted IP Additionally, we is to show behind our and paid IP, give be strength able a with to many investors' is them we'll great the our the forward. it value Both can valuable. patents. over to and developed settlement in which protection value moving we've And our of and a
